Progress in drug therapy for advanced triple-negative breast cancer
10.12092/j.issn.1009-2501.2020.04.019
- VernacularTitle: 晚期三阴性乳腺癌的药物治疗进展
- Author:
Quanming ZHAO
1
Author Information
1. Second Clinical Medical College of Shanxi Medical University
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Endocrine therapy;
Immunotherapy;
Targeted therapy;
Triple-negative breast cancer
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(4):475-480
- CountryChina
- Language:Chinese
-
Abstract:
Triple-negative breast cancer is estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 negative breast cancer. The lack of specific treatment targets, there are few effective therapy for advanced triple- negative breast cancer. This article will review the current progress in drug therapy for advanced triple-negative breast cancer, including chemotherapy, targeted therapy, endocrine therapy and immunotherapy, in order to provide reference for clinical treatment.
